The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).
 
Aparna Raj Parikh
Consulting or Advisory Role - Driver, Inc; Driver, Inc; Driver, Inc; Driver, Inc; Eisai; Eisai; Eisai; Eisai; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; PureTech; PureTech; PureTech; PureTech
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Eisai; Eisai; Eisai; Eisai
 
Mihir Rajurkar
No Relationships to Disclose
 
Emily E. Van Seventer
No Relationships to Disclose
 
Angelo J. Gemma
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
 
Jeffrey William Clark
Consulting or Advisory Role - Emas pharma; Emas pharma; Emas pharma; Emas pharma
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
 
Lipika Goyal
Consulting or Advisory Role - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics; Clinical Genomics; Clinical Genomics; Clinical Genomics; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Intrinsic LifeSciences (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
Jennifer Yon-Li Wo
No Relationships to Disclose
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; Avidity Biosciences; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Avidity Nanomedicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; C4 Therapeutics; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; Elicio Therapeutics; FOGPharma; FOGPharma; FOGPharma; FOGPharma; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Fount Therapeutics; Genentech; Genentech; Genentech; Genentech; Loxo; Loxo; Loxo; Loxo; Merrimack; Merrimack; Merrimack; Merrimack; N-of-One; N-of-One; N-of-One; N-of-One; Novartis; Novartis; Novartis; Novartis; nRichDx; nRichDx; nRichDx; nRichDx; Revolution Medicines; Revolution Medicines; Revolution Medicines; Revolution Medicines; Roche; Roche; Roche; Roche; Roivant; Roivant; Roivant; Roivant; Shionogi; Shionogi; Shionogi; Shionogi; Shire; Shire; Shire; Shire; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Symphogen; Symphogen; Symphogen; Symphogen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio; Warp Drive Bio
Research Funding - Asana Biosciences; Asana Biosciences; Asana Biosciences; Asana Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Sanofi; Sanofi; Sanofi; Sanofi
 
Alexander Solovyov
Patents, Royalties, Other Intellectual Property - Patent for targeting repeat RNAs and their use as novel biomarkers; Patent for targeting repeat RNAs and their use as novel biomarkers; Patent for targeting repeat RNAs and their use as novel biomarkers; Patent for targeting repeat RNAs and their use as novel biomarkers
 
Benjamin Greenbaum
Stock and Other Ownership Interests - ROME Therapeutics; ROME Therapeutics; ROME Therapeutics; ROME Therapeutics
Patents, Royalties, Other Intellectual Property - Patent-- relating to targeting repeat RNAs and their use as novel biomarkers; Patent-- relating to targeting repeat RNAs and their use as novel biomarkers; Patent-- relating to targeting repeat RNAs and their use as novel biomarkers; Patent-- relating to targeting repeat RNAs and their use as novel biomarkers
 
Annamaria Szabolcs
No Relationships to Disclose
 
Eric C. Tai
No Relationships to Disclose
 
Jasmin Joseph
No Relationships to Disclose
 
Vishal Thapar
No Relationships to Disclose
 
Hui Zheng
No Relationships to Disclose
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Acworth Pharmaceuticals; Acworth Pharmaceuticals; Acworth Pharmaceuticals; MPM Capital; MPM Capital; MPM Capital; MPM Capital
Honoraria - Research to Practice; Research to Practice; Research to Practice; Research to Practice; UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; MPM Capital; MPM Capital; MPM Capital; MPM Capital; Oncorus; Oncorus; Oncorus; Oncorus; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst); Stand up to Cancer (Inst); Stand up to Cancer (Inst); Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; Johns Hopkins University Press; Johns Hopkins University Press; Johns Hopkins University Press; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties; McGraw Hill Chapter Royalties
Other Relationship - TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics
 
David Tsai Ting
Stock and Other Ownership Interests - PanTher Therapeutics; PanTher Therapeutics; PanTher Therapeutics; PanTher Therapeutics
Honoraria - Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems; Ventana Medical Systems
Consulting or Advisory Role - Merrimack; Merrimack; Merrimack; Merrimack
Research Funding - ACD Biotechne; ACD Biotechne; ACD Biotechne; ACD Biotechne
Patents, Royalties, Other Intellectual Property - Patent licensed to PanTher Therapeutics by my institution (Partners Health care). No royalty payments have been received; Patent licensed to PanTher Therapeutics by my institution (Partners Health care). No royalty payments have been received; Patent licensed to PanTher Therapeutics by my institution (Partners Health care). No royalty payments have been received; Patent licensed to PanTher Therapeutics by my institution (Partners Health care). No royalty payments have been received